CBAK Energy Technology, Inc. is a China-based manufacturer of lithium-ion and sodium-ion rechargeable battery cells, with facilities in Dalian and Nanjing. Coverage of the stock is unusually thin. TipRanks currently lists zero analysts actively covering the name, and aggregators such as Yahoo Finance and Investing.com show a single 12-month price target of $1.50. That figure traces to Zacks Small-Cap Research (analyst Brian Lantier), which has maintained a $1.50 valuation target across several reports and reaffirmed it in February 2026.
With only one attributable, current target rather than a genuine multi-analyst consensus, this article does not present $1.50 as an official "analyst consensus." Instead, $1.50 is treated as a realistic price objective that is being discussed publicly in research reports and data platforms. For context, the published single-target range is $1.50 to $1.50, so there is no meaningful spread among analysts to weigh.
The stock last closed near $1.05, within a 52-week range of roughly $0.46 to $1.55. Reaching $1.50 would require an advance of about 43% from that level, a substantial move for a small-cap stock with a market capitalization near $93 million. The path would likely depend on the company converting its top-line momentum into sustainable profitability as newly installed capacity ramps up.
The company's revenue has been growing quickly. In its most recent quarterly update, consolidated revenue rose roughly 132% year over year to about $58.8 million, and trailing twelve-month revenue growth is around 50%. Management has guided toward record consolidated sales as new capacity comes online, including the Dalian 40135 line (2.3 GWh) commissioned at the end of 2025 and two additional Nanjing Phase II lines adding roughly 3.0 GWh. The raw-materials subsidiary, Hitrans, has also improved, with revenue up about 123% year over year to roughly $89 million, and cathode-material price hikes in China could provide a tailwind.
The principal obstacle is profitability. Full-year 2025 gross margin fell to about 9.4% from 23.7% in 2024, reflecting higher unit costs and lower yields during capacity transitions, and the company has continued to post net losses. Balance-sheet strain is another concern: the company's independent auditors have expressed substantial doubt about its ability to continue as a going concern. Any delay in the Dalian or Nanjing ramp-up, further margin compression, or renewed U.S.-China trade friction could keep the stock well below $1.50.
The $0.46 area marks the 52-week low and a key support zone, while $1.55 is the 52-week high and a significant resistance level just above the $1.50 objective. The $1.00 round-number level is a psychological zone that the stock has traded around. A durable move toward $1.50 would require the shares to first hold above $1.00 and then challenge the prior high near $1.55.
The $1.50 figure reflects a research-horizon valuation, commonly viewed over roughly a 12-month window, though no firm timeline is guaranteed. Investors should watch the upcoming earnings release, guidance on gross-margin recovery and capacity ramp-up timing, any news on the Anker Innovations partnership, and updates on the going-concern assessment. Changes to the single published target, or the addition of new coverage, would also be worth monitoring.
For traders who want a systematic way to track names like CBAT, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Exploring these signals can be a useful complement to fundamental research.
Can CBAT reach $1.50? The target implies a substantial move of about 43% from the current price, and it rests on a single, publicly discussed valuation rather than a broad analyst consensus. Rapid revenue growth, a major capacity expansion, and a recovering raw-materials segment argue in its favor, while margin compression, persistent losses, and a going-concern warning are significant counterweights. The stock's own 52-week high of $1.55 shows the level is not unprecedented, but reaching and holding $1.50 would likely require evidence that new capacity is converting into durable profitability. No outcome is guaranteed, and investors should monitor earnings, margins, and the balance sheet closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that CBAT and STI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CBAT and STI's prices will move in lockstep.
| Ticker / NAME | Correlation To CBAT | 1D Price Change % | ||
|---|---|---|---|---|
| CBAT | 100% | +10.71% | ||
| STI - CBAT | 29% Poorly correlated | +0.99% | ||
| ENS - CBAT | 26% Poorly correlated | -2.43% | ||
| ESP - CBAT | 25% Poorly correlated | +0.83% | ||
| RUN - CBAT | 25% Poorly correlated | +4.13% | ||
| ENVX - CBAT | 24% Poorly correlated | -4.17% | ||
More | ||||
| Ticker / NAME | Correlation To CBAT | 1D Price Change % |
|---|---|---|
| CBAT | 100% | +10.71% |
| Producer Manufacturing category (346 stocks) | -3% Poorly correlated | +1.04% |